DUPILABNCT06169527
A Long-term Data Collection Study of Participants in France Aged 6 Years Old or More With Atopic Dermatitis Receiving Dupilumab
At risk: Primary completion moved 56 days later.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 9 versions: 9 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Eligibility criteria expanded, about 9 words
- Primary endpoints: details revised at 3 of 26 entries
- Primary and study completion pushed from May 10, 2028 to Jul 5, 2028
- Minor Enrollment target: 302 to 303
- Site details revised at 13 of 42 sites
- Minor Trial status: Recruiting to Active, Not Recruiting
- Enrollment target: estimated 500 to confirmed 302
- Primary and study completion dates: Nov 29, 2027 to May 10, 2028
- Site details revised at 42 of 42 sites
- Minor Study sites: 41 to 42v6
- Minor Study sites: 40 to 41v5
Show 3 earlier versionsHide 3 earlier versions
- Minor Study sites: 33 to 40v4
- Notable Primary endpoints: 25 to 26
- Study sites: 4 to 33
- Notable Trial status: Not Yet Recruiting to Recruiting
- Study sites: 0 to 4
- Start date changed from estimate of Dec 6, 2023 to Nov 28, 2023
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Demographic characteristics of participants who receive dupilumab for AD
Timeframe: At baseline
Weight characteristics of participants who receive dupilumab for AD
Timeframe: At baseline
Height characteristics of participants who receive dupilumab for AD
Timeframe: At baseline
Medical history characteristics of participants who receive dupilumab for AD
Timeframe: At baseline
Comorbidities and treatments change from baseline
Timeframe: At baseline, month 3, month 6, month 12, month 18, month 24, month 30, month 36
Atopic comorbidities and treatments change from baseline
Timeframe: At baseline, month 3, month 6, month 12, month 18, month 24, month 30, month 36
Change from baseline in lifestyle habits of participants who receive dupilumab for AD
Timeframe: At baseline, month 3, month 6, month 12, month 18, month 24, month 30, month 36 if applicable
Change from baseline in dupilumab dose
Timeframe: At baseline, month 3, month 6, month 12, month 18, month 24, month 30, month 36
Change from baseline in dupilumab administration
Timeframe: At baseline, month 3, month 6, month 12, month 18, month 24, month 30, month 36
Change from baseline in dupilumab compliance with treatment
Timeframe: At baseline, month 3, month 6, month 12, month 18, month 24, month 30, month 36
Change from baseline in dupilumab temporary or permanent discontinuation
Timeframe: At baseline, month 3, month 6, month 12, month 18, month 24, month 30, month 36
Change from baseline in dupilumab treatment switch to another therapy
Timeframe: At baseline, month 3, month 6, month 12, month 18, month 24, month 30, month 36
Change from baseline in dupilumab treatment for concomitant AD treatments
Timeframe: At baseline, month 3, month 6, month 12, month 18, month 24, month 30, month 36
Change in patient's treatment satisfaction score using the Patient Global Assessment of Treatment Effect (PGATE)
Timeframe: At month 6, month 12, month 18, month 24, month 30, month 36
Change in eczema severity using the Eczema Area and Severity Index (EASI)
Timeframe: At baseline, month 6, month 12, month 18, month 24, month 30, month 36
Change in AD disease control using the Atopic Dermatitis Control Tool (ADCT)
Timeframe: At baseline, month 6, month 12, month 18, month 24, month 30, month 36
Change in itch assessment
Timeframe: At baseline, month 6, month 12, month 18, month 24, month 30, month 36
Change in sleep disturbance NRS
Timeframe: At baseline, month 6, month 12, month 18, month 24, month 30, month 36
Change in global patient's disease evaluation using the Patient Global Assessment of Disease Severity (PGADS)
Timeframe: At baseline, month 6, month 12, month 18, month 24, month 30, month 36
Change in global patient's disease evaluation using the Caregiver Global Assessment of Disease (CGAD)
Timeframe: At baseline, month 6, month 12, month 18, month 24, month 30, month 36
Change in Dermatology Life Quality Index (DLQI)
Timeframe: At baseline, month 6, month 12, month 18, month 24, month 30, month 36
Change in Dermatitis Family Impact Questionnaire (DFI)
Timeframe: At baseline, month 6, month 12, month 18, month 24, month 30, month 36
Change in European Quality of Life-5 Dimensions-3 level score (EQ-5D-3L)
Timeframe: At baseline, month 6, month 12, month 18, month 24, month 30, month 36
Change in Work Productivity and Activity Impairment Questionnaire, Atopic Dermatitis (WPAI-AD)
Timeframe: At month 6, month 12, month 18, month 24, month 30, month 36
Number of Adverse Events (AE)
Timeframe: At baseline, month 3, month 6, month 12, month 18, month 24, month 30, month 36
Change from baseline in Drug Survival
Timeframe: At baseline, month 3, month 6, month 12, month 18, month 24, month 30, month 36
Arms and interventions
Participants with AD treated with dupilumab
Patients ≥6 years of age in whom dupilumab therapy was initiated to treat their AD according to French-specific prescribing information.
Drugs: Dupilumab
Sites
42 sites in 1 country